دورية أكاديمية

Early B cell changes predict autoimmunity following combination immune checkpoint blockade.

التفاصيل البيبلوغرافية
العنوان: Early B cell changes predict autoimmunity following combination immune checkpoint blockade.
المؤلفون: Das, Rituparna1 (AUTHOR), Bar, Noffar1 (AUTHOR), Ferreira, Michelle1,2 (AUTHOR), Newman, Aaron M3,4 (AUTHOR), Zhang, Lin1 (AUTHOR), Bailur, Jithendra Kini1 (AUTHOR), Bacchiocchi, Antonella5 (AUTHOR), Kluger, Harriet1 (AUTHOR), Wei, Wei6 (AUTHOR), Halaban, Ruth5 (AUTHOR), Sznol, Mario1,7 (AUTHOR), Dhodapkar, Madhav V1,7,8 (AUTHOR), Dhodapkar, Kavita M2,7 (AUTHOR)
المصدر: Journal of Clinical Investigation. Feb2018, Vol. 128 Issue 2, p715-720. 6p.
مستخلص: Combination checkpoint blockade (CCB) targeting inhibitory CTLA4 and PD1 receptors holds promise for cancer therapy. Immune-related adverse events (IRAEs) remain a major obstacle for the optimal application of CCB in cancer. Here, we analyzed B cell changes in patients with melanoma following treatment with either anti-CTLA4 or anti-PD1, or in combination. CCB therapy led to changes in circulating B cells that were detectable after the first cycle of therapy and characterized by a decline in circulating B cells and an increase in CD21lo B cells and plasmablasts. PD1 expression was higher in the CD21lo B cells, and B cell receptor sequencing of these cells demonstrated greater clonality and a higher frequency of clones compared with CD21hi cells. CCB induced proliferation in the CD21lo compartment, and single-cell RNA sequencing identified B cell activation in cells with genomic profiles of CD21lo B cells in vivo. Increased clonality of circulating B cells following CCB occurred in some patients. Treatment-induced changes in B cells preceded and correlated with both the frequency and timing of IRAEs. Patients with early B cell changes experienced higher rates of grade 3 or higher IRAEs 6 months after CCB. Thus, early changes in B cells following CCB may identify patients who are at increased risk of IRAEs, and preemptive strategies targeting B cells may reduce toxicities in these patients. [ABSTRACT FROM AUTHOR]
قاعدة البيانات: Academic Search Index